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IntroductIon
Dementia with Lewy Bodies (DLB) is a 
 neurodegenerative disorder that affects cog-
nition, behavior, movement, and autonomic 
function. Along with a gradually developing 
dementia, it is characterized by fluctuating 
cognition, spontaneous parkinsonism, and 
recurrent visual hallucinations. This article 
provides a brief overview of neuroimaging, 
biomarkers, and management in DLB.
neuroImagIng and other 
auxIlIary InvestIgatIons
In structural imaging with MRI, relative 
preservation of hippocampus and medial 
temporal lobes as compared to atrophy in 
these regions in patients with AD patients 
have been described in pathologically con-
firmed DLB patients (1). Sabattoli et al. 
found that there was mild hippocampal 
atrophy (10–20%) in DLB patients com-
pared to control group, but it was less than 
seen in AD (2). There is, however, consider-
able overlap between AD and DLB, and the 
utility of MRI for differential diagnosis is lim-
ited. In a recent study, Lewy Body (LB), but 
not AD-type pathology was associated with 
reduced amygdala volume in pathologically 
verified DLB cases, but neither LB nor AD 
pathology was associated with volume loss in 
hippocampus or entorhinal cortex, suggest-
ing other neuropathological factors account-
ing for atrophy in these structures (3). Others 
suggested that hippocampal atrophy on MRI 
may be associated with neurofibrillary tangles 
in patients with LB pathology (4). Atrophy in 
other cortical and subcortical structures has 
also been reported in DLB, including stria-
tum, substantia innominata, hypothalamus, 
and dorsal midbrain (4). The rate of overall 
cerebral atrophy in longitudinal MRI studies 
has been reported to be 1.4% per year, three 
times more than that seen in controls, but 
less than that seen in AD (2% per year) (5).
In a Diffusion Tensor Imaging study, 
changes [increased diffusion (D) and 
decreased fractional anisotropy (FA) val-
ues] in corpus callosum and pericallosal 
areas were found in DLB patients as com-
pared to normal controls (6), white matter 
was also affected in the frontal, parietal, and 
occipital areas. In another study DLB group 
had reduced FA in the precuneus area com-
pared to controls and AD patients (7). Areas 
of reduced FA in DLB vs. controls were also 
found primarily in parietooccipital white 
matter tracts whereas the changes were 
more diffuse in AD; compared to AD, DLB 
was also associated with reduced FA in pons 
and left thalamus (8). This study suggests 
that pattern of DTI changes in AD and DLB 
are different. Resting state fMRI studies sug-
gested increased functional connectivity 
between the right posterior cingulate and 
other brain areas (9).
SPECT and PET studies have demon-
strated decreased glucose metabolism and 
perfusion deficits in parietal and occipital 
areas in DLB (10, 11). However, occipi-
tal hypometabolism is not always present 
and FDG-PET changes may be similar 
to that seen in AD. Reduced uptake of 18 
F-fluorodopa in the striatum may distin-
guish DLB from AD with high sensitivity 
and specificity (12). Several studies, using 
123-I-beta-CIT SPECT, demonstrated 
reduced dopamine transporter binding in 
the caudate and posterior putamen in DLB 
compared to AD patients (13, 14), but no 
difference between DLB and Parkinson’s 
Disease (PD) patients. Similarly, thoracic 
SPECT imaging using 123-I metaiodoben-
zylguanidine (MIBG), a marker of post-
ganglionic cardiac sympathetic innervation, 
shows reduced cardiac MIBG uptake in 
DLB and PD patients as opposed to normal 
findings in AD (15). It was suggested that 
combining SPECT and MIBG scintigraphy 
could increase the  diagnostic accuracy for 
DLB (16). Pittsburgh compound B (PiB) is 
an in vivo indicator of β-amyloid load, 80% 
of DLB cases were found to have increased 
amyloid load in 11C-PIB PET, whereas only 
20% of patients with Parkinson’s Disease 
Dementia (PD-D) have this finding (17).
Standard EEG may show early slowing 
of background activity in DLB patients 
compared with AD as well as epoch by 
epoch fluctuations. Frontal intermittent 
delta activity and transient temporal slow 
waves are other changes which are more 
common in DLB than in AD (18). Video-
polysomnography, including surface elec-
tromyography (EMG) of the chin and 
extremities is necessary for the diagnosis 
of RBD, which is a common feature of DLB.
cerebrospInal FluId bIomarkers 
In dlb
Currently, there are no blood or CSF mark-
ers which can be used for diagnosis, to fol-
low disease progression or as an outcome 
parameter for therapeutic interventions in 
DLB. Alpha-synuclein has been studied as 
a potential biomarker for DLB, but results 
have been controversial (19, 20). Amyloid 
beta 40–42 in CSF is a biomarker for AD, 
several studies reported lower amyloid beta 
40–42 levels also in DLB compared to con-
trols and PD-D cases (21, 22). In addition, 
Mulugeta et al. suggested CSF amyloid-38 
as a diagnostic biomarker for DLB (23); 
A-42/A-38 ratio discriminated AD from 
DLB with a sensitivity of 78% and a speci-
ficity of 67%.
management oF patIents wIth dlb
Management of DLB includes both 
non-pharmacological and pharmaco-
logical approaches. Non-pharmacologic 
approaches have the potential to reduce clin-
ical symptoms and functional  impairment. 
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patients for 12 weeks (31). Patients given 
5 or 10 mg donepezil showed greater 
improvement in the majority of the 
 cognitive and behavioral scales, including 
MMSE and NPI. Donepezil treatment also 
led to improved global function, as meas-
ured by CIBIC-plus and reduced caregiver 
burden at the highest dose. Patients tak-
ing donepezil were less apathetic, less anx-
ious, had less cognitive fluctuation, fewer 
delusions and hallucinations compared to 
placebo patients. Approximately 8% of the 
study population withdrew due to adverse 
effects, and the prevalence of withdrawal 
or adverse effects, including typical cho-
linergic side effects, did not differ among 
treatment groups.
Changes in glutamatergic activity have 
been reported in patients with DLB (32). 
Uncompetitive N-methyl-d-aspartate 
antagonist memantine was tested in two 
randomized placebo controlled studies 
including DLB patients; the results were 
however not consistent (33, 34). The larger 
study in patients with Lewy-body-related 
dementias included 199 patients, of which 
121 had PD-D and 78 had DLB (34). At 
week 24, patients treated with memantine 
had greater improvements in global status 
[as measured by clinical global impression 
of change (CGIC) score] than did patients 
who received placebo; improvements 
were predominantly in the DLB group. 
Behavioral symptoms as assessed with 
NPI total score significantly improved in 
the DLB group only. Cognitive test scores, 
activities of daily living scores, motor 
symptoms, or caregiver burden scores 
did not show significant improvements 
in either patient group. Adverse events 
in the two treatment groups were similar, 
except for slightly more sedation in the 
memantine treated patients. In another, 
smaller randomized trial of memantine in 
patients with Lewy-body-related demen-
tias, including both patients with DLB or 
PD-D significantly improved mean CGIC 
score was observed in the total popula-
tion after 6 months of treatment, the dif-
ference was driven by a larger efficacy in 
the PD-D group (33). NPI scores showed 
a statistically significantly improvement 
in the memantine group as compared 
to placebo in the DLB group, but not in 
the PD-D population. No statistically 
significant differences were observed in 
Recognition of potentially treatable sensory 
impairments such as impaired vision and 
environmental changes such as improv-
ing lighting may reduce hallucinations and 
falls. Behavioral symptoms may be relieved 
or reduced by education and behavioral 
modifications of caregivers.
All drugs with anticholinergic effects, 
e.g., tricyclic antidepressants, anticholin-
ergics, antispasmodics should be discon-
tinued as they have the potential to further 
impair cognition, exacerbate psychotic 
symptoms, and may be associated with 
orthostatic hypotension in patients with 
DLB (24). l-DOPA should be preferred 
to treat motor symptoms, it should be 
started at low doses and increased slowly 
to the minimum required dose. Patients 
with DLB may be less responsive to levo-
dopa therapy than those with Parkinson’s 
disease. Only 30–50% of patients improve 
significantly (25, 26). Other antiparkinso-
nian agents, including monoamine oxidase 
B inhibitors, amantadine, and dopamine 
agonists are usually less tolerable in DLB 
patients.
Orthostatic hypotension can be treated 
with hydration, increased dietary salt intake 
or with salt tablets, avoidance of prolonged 
bed rest, thigh-high compression stockings, 
efforts to stand up slowly, and avoidance of 
medications that contribute to orthostasis. 
If these measures are ineffective, fludro-
cortisone or midodrine can be considered. 
REM sleep behavior disorder can be treated 
with low dose clonazepam (0.25–1.0 mg) 
at bedtime, however clonazepam has 
the potential to worsen the symptoms of 
obstructive sleep apnea (27). Melatonin 
may also be effective at a dose of 3–12 mg, 
either as monotherapy or in conjunction 
with clonazepam. Although evidence base 
in DLB is weak, drugs such as modafinil and 
methylphenidate can be considered to treat 
excessive daytime sleepiness.
Visual hallucinations are often the most 
troubling neuropsychiatric feature in DLB, 
they do not require drug treatment if they 
are not frightening. Atypical antipsychot-
ics are used to treat psychotic symptoms, 
but they should be used with great caution 
in DLB, as some patients may show severe 
neuroleptic sensitivity which is not predict-
able in an individual patient (28). In addi-
tion, antipsychotics may increase the risk of 
cerebrovascular events and death in elderly 
patients with dementia (29). As  reductions 
in cholinergic activity correlate with 
 hallucinations, cholinesterase  inhibitors 
may be considered for management of 
hallucinations and delusions, if they are 
not severe, before using a neuroleptic (30, 
31). If the symptoms are refractory, cause 
significant impairment or severe burden 
for caregivers, quetiapine, and clozapine 
can be considered. Initial doses should be 
low and the dose should be titrated slowly 
while monitoring for functional decline. 
Neuroleptics can cause orthostatic hypoten-
sion and blood pressure monitoring may be 
necessary in some patients.
Patients with DLB have severe cholin-
ergic deficits. Results from randomized 
controlled trials with cholinesterase inhib-
itors rivastigmine and donepezil indicated 
improvements in cognitive function and 
behavioral symptoms (30, 31). McKeith 
et al. reported a multicenter, randomized, 
controlled study of 120 patients with DLB 
using rivastigmine 6–12 mg/day or placebo 
for 20 weeks (30). Although there was a 
slight improvement in mean MMSE score 
in the rivastigmine group at week 20, this 
was not statistically significant compared 
to placebo nor was the clinician-assessed 
global status. Change from baseline in 
mean Neuropsychiatric Inventory (NPI, 
10 items) score was not significantly dif-
ferent between the two groups in the 
intention-to-treat, but statistically sig-
nificant in favor of rivastigmine in the 
observed cases analysis. More than twice 
as many patients on rivastigmine (63.4%) 
than on placebo (30.0%) showed at least a 
30% improvement from baseline in their 
NPI-4 scores (P ≤ 0.001). Apathy, anxiety, 
delusions, and hallucinations were the 
symptoms to show most response. There 
was also a significant improvement in a 
computerized test of attention, choice 
reaction time. Improvements seen with 
rivastigmine returned to baseline during 
a 3-week washout period. Nausea (37%), 
vomiting (25%), anorexia (19%), and som-
nolence (9%) were the most common side 
effects. Worsening of parkinsonism was 
not reported, although emergent tremor 
was noted in four rivastigmine-treated 
patients.
In another large randomized, placebo 
controlled study the effect of donepezil 
(3, 5, 10 mg/day) was assessed in 140 DLB 
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 individual cognitive tests, ADCS-activities 
of Daily Living or Zarit caregiver burden 
scores. The incidence of adverse events and 
number of discontinuations due to adverse 
events were similar in both groups.
In summary, cholinesterase  inhibitors 
such as rivastigmine and donepezil 
should be considered in all patients with 
a  diagnosis with DLB, taking into account 
potential benefits and risks. The data 
on benefits of memantine are less clear, 
memantine may be considered in appro-
priate patients with prominent behavioral 
symptoms.
conclusIon
Structural and functional imaging may help 
in the diagnosis and differential diagnosis of 
DLB, there are however no unique patterns, 
SPECT imaging of dopamine transporter 
can differentiate from AD. Currently there is 
no validated biomarker for DLB, an impor-
tant target for future research is to improve 
the accuracy of diagnosis by developing sen-
sitive biomarkers. Cholinesterase inhibitors 
remain the first choice therapy for cognitive 
impairment. There are as yet no disease-
modifying agents, new treatments are 
urgently required for DLB which is second 
most frequent degenerative dementia fol-
lowing AD.
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